{"id":2711,"date":"2021-06-24T11:21:00","date_gmt":"2021-06-24T09:21:00","guid":{"rendered":"https:\/\/www.multiplesclerosis.cz\/?p=2711"},"modified":"2025-08-20T08:52:58","modified_gmt":"2025-08-20T09:52:58","slug":"multiple-sclerosis-neuromyelitis-optica-and-covid-19-pandemic-year-in-the-czech-republic","status":"publish","type":"post","link":"https:\/\/multiplesclerosis-app-aca9g6eranbfeyeg.northeurope-01.azurewebsites.net\/en\/2021\/06\/24\/roztrousena-skleroza-neuromyelitis-optica-a-covid-19-pandemicky-rok-v-cesku\/","title":{"rendered":"Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia"},"content":{"rendered":"\n

Vzhledem k v\u00fdskytu nov\u00e9ho koronaviru COVID-19 vznikly obavy ohledn\u011b pr\u016fb\u011bhu tohoto onemocn\u011bn\u00ed u pacient\u016f s roztrou\u0161enou skler\u00f3zou (RS) a neuromyelitis optica spectrum disorder (NMOSD). Tato studie si kladla za c\u00edl vyhodnotit v\u00fdskyt, z\u00e1va\u017enost a rizikov\u00e9 faktory pro z\u00e1va\u017en\u011bj\u0161\u00ed pr\u016fb\u011bh COVID-19 mezi pacienty s RS a NMOSD. V\u00fdzkum byl proveden prost\u0159ednictv\u00edm \u010desk\u00e9ho celon\u00e1rodn\u00edho registru ReMuS a zahrnoval data z 12 RS center, kter\u00e1 pokr\u00fdvaj\u00ed 70 % \u010desk\u00e9 populace pacient\u016f s RS a NMOSD. V\u00fdsledky studie poskytuj\u00ed d\u016fle\u017eit\u00e9 poznatky o rizic\u00edch spojen\u00fdch s onemocn\u011bn\u00edm COVID-19 u t\u011bchto pacient\u016f, a to zejm\u00e9na v souvislosti s jejich l\u00e9\u010dbou a z\u00e1kladn\u00edmi charakteristikami.<\/p>\n\n\n\n

\"\"<\/a><\/figure>
\n

Stastna, D., Menkyova, I., Drahota, J., Mazouchova, A., Adamkova, J., Ampapa, R., Grunermelova, M., Peterka, M., Recmanova, E., Rockova, P., Rous, M., Stetkarova, I., Valis, M., Vachova, M., Woznicova, I., & Horakova, D. (2021). Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia<\/em>. In Multiple Sclerosis and Related Disorders <\/strong>(Vol. 54, p. 103104). Elsevier BV. https:\/\/doi.org\/10.1016\/j.msard.2021.103104<\/a> PMID: 34216998<\/p>\n<\/div><\/div>\n\n\n\n

Abstrakt<\/h2>\n\n\n\n

\u00davod:<\/strong> Kdy\u017e se objevilo nov\u00e9 koronavirov\u00e9 onemocn\u011bn\u00ed COVID-19, vznikly obavy ohledn\u011b jeho pr\u016fb\u011bhu u pacient\u016f s roztrou\u0161enou skler\u00f3zou (RS) a poruchou spektra neuromyelitidy optiky (NMOSD). Tato studie m\u011bla za c\u00edl vyhodnotit v\u00fdskyt, z\u00e1va\u017enost a rizikov\u00e9 faktory pro z\u00e1va\u017en\u011bj\u0161\u00ed pr\u016fb\u011bh COVID-19 u pacient\u016f s RS a NMOSD.<\/p>\n\n\n\n

Metody: <\/strong>Od 1. b\u0159ezna 2020 do 28. \u00fanora 2021 12 RS center, kter\u00e9 p\u0159edstavuj\u00ed 70 % \u010desk\u00e9 populace pacient\u016f s RS a NMOSD, hl\u00e1silo laboratorn\u011b potvrzen\u00e9 p\u0159\u00edpady COVID-19 prost\u0159ednictv\u00edm \u010desk\u00e9ho celon\u00e1rodn\u00edho registru pacient\u016f s RS a NMOSD (ReMuS). Hlavn\u00edm v\u00fdsledkem byla z\u00e1va\u017enost COVID-19 hodnocen\u00e1 na 8bodov\u00e9 \u0161k\u00e1le s hranic\u00ed na \u00farovni 4 (radiologicky potvrzen\u00e1 pneumonie) podle hodnocen\u00ed z\u00e1va\u017enosti COVID-19 Sv\u011btovou zdravotnickou organizac\u00ed (WHO).<\/p>\n\n\n\n

V\u00fdsledky:<\/strong> Identifikovali jsme 958 pacient\u016f s RS a 13 pacient\u016f s NMOSD, 50 pacient\u016f s RS a 4 pacienti s NMOSD m\u011bli pneumonii, 3 pacienti s RS a 2 pacienti s NMOSD zem\u0159eli. V\u00fdskyt COVID-19 u pacient\u016f s RS se zd\u00e1 b\u00fdt podobn\u00fd jako v obecn\u00e9 \u010desk\u00e9 populaci. Multivariantn\u00ed logistick\u00e1 regrese zjistila, \u017ee vy\u0161\u0161\u00ed index t\u011blesn\u00e9 hmotnosti (BMI [OR 1,07, 95% CI, 1,00-1,14]), vy\u0161\u0161\u00ed v\u011bk (OR na 10 let 2,01, 95% CI, 1,41-2,91), l\u00e9\u010dba vysok\u00fdmi d\u00e1vkami glukokortikoid\u016f b\u011bhem 2 m\u011bs\u00edc\u016f p\u0159ed n\u00e1stupem COVID-19 (OR 2,83, 95% CI, 0,10-7,48) a terapie anti-CD20 (OR 7,04, 95% CI, 3,10-15,87) byly nez\u00e1visl\u00e9 prom\u011bnn\u00e9 spojen\u00e9 s pneumoni\u00ed u pacient\u016f s RS. Zv\u00fd\u0161en\u00e9 riziko pneumonie u pacient\u016f s RS l\u00e9\u010den\u00fdch anti-CD20 ve srovn\u00e1n\u00ed s pacienty s jinou l\u00e9\u010dbou modifikuj\u00edc\u00ed onemocn\u011bn\u00ed (stejn\u00fd v\u011bk, pohlav\u00ed, BMI, l\u00e9\u010dba vysok\u00fdmi d\u00e1vkami glukokortikoid\u016f b\u011bhem 2 m\u011bs\u00edc\u016f p\u0159ed n\u00e1stupem COVID-19, p\u0159\u00edtomnost plicn\u00ed komorbidity) bylo potvrzeno metodou p\u00e1rov\u00e1n\u00ed podle propensity score (OR 8,90, 95% CI, 3,04-33,24). Zpr\u00e1vy o infekci COVID-19 u pacient\u016f s NMOSD jsou vz\u00e1cn\u00e9, av\u0161ak dosavadn\u00ed dostupn\u00e1 data nazna\u010duj\u00ed vysok\u00e9 riziko z\u00e1va\u017en\u011bj\u0161\u00edho pr\u016fb\u011bhu COVID-19 a vy\u0161\u0161\u00ed m\u00edru \u00famrtnosti u pacient\u016f s NMOSD. V na\u0161\u00ed kohort\u011b m\u011blo 4 pacient\u016f s NMOSD (30,77 %) z\u00e1va\u017en\u011bj\u0161\u00ed pr\u016fb\u011bh COVID-19 a 2 pacienti (15,39 %) zem\u0159eli.<\/p>\n\n\n\n

Z\u00e1v\u011br:<\/strong> V\u011bt\u0161ina pacient\u016f s RS m\u011bla m\u00edrn\u00fd pr\u016fb\u011bh COVID-19, na rozd\u00edl od pacient\u016f s NMOSD, nicm\u00e9n\u011b vy\u0161\u0161\u00ed BMI a v\u011bk, terapie anti-CD20 a l\u00e9\u010dba vysok\u00fdmi d\u00e1vkami glukokortikoid\u016f b\u011bhem 2 m\u011bs\u00edc\u016f p\u0159ed n\u00e1stupem COVID-19 byly spojeny s pneumoni\u00ed. Na z\u00e1klad\u011b t\u00e9to studie jsme ji\u017e zah\u00e1jili \u010dasn\u00e9 pod\u00e1v\u00e1n\u00ed monoklon\u00e1ln\u00edch protil\u00e1tek proti SARS-CoV-2 a preferen\u010dn\u00ed o\u010dkov\u00e1n\u00ed u rizikov\u00e9 skupiny pacient\u016f.<\/p>\n\n\n\n

\"\"<\/a><\/figure>
\n

Cel\u00fd \u010dl\u00e1nek si m\u016f\u017eete v angli\u010dtin\u011b p\u0159e\u010d\u00edst na webu \u010dasopisu Multiple Sclerosis and Related Disorders<\/a><\/strong>.<\/p>\n<\/div><\/div>\n","protected":false},"excerpt":{"rendered":"

The emergence of the novel coronavirus COVID-19 has raised concerns about the course of this disease in patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). This study aimed to evaluate the incidence, severity, and risk factors for a more severe course of COVID-19 among patients with MS and NMOSD ...<\/p>","protected":false},"author":3,"featured_media":2985,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[4],"tags":[5],"class_list":["post-2711","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publikace","tag-medical-professionals-only"],"_links":{"self":[{"href":"https:\/\/multiplesclerosis-app-aca9g6eranbfeyeg.northeurope-01.azurewebsites.net\/en\/wp-json\/wp\/v2\/posts\/2711","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/multiplesclerosis-app-aca9g6eranbfeyeg.northeurope-01.azurewebsites.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/multiplesclerosis-app-aca9g6eranbfeyeg.northeurope-01.azurewebsites.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/multiplesclerosis-app-aca9g6eranbfeyeg.northeurope-01.azurewebsites.net\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/multiplesclerosis-app-aca9g6eranbfeyeg.northeurope-01.azurewebsites.net\/en\/wp-json\/wp\/v2\/comments?post=2711"}],"version-history":[{"count":1,"href":"https:\/\/multiplesclerosis-app-aca9g6eranbfeyeg.northeurope-01.azurewebsites.net\/en\/wp-json\/wp\/v2\/posts\/2711\/revisions"}],"predecessor-version":[{"id":5140,"href":"https:\/\/multiplesclerosis-app-aca9g6eranbfeyeg.northeurope-01.azurewebsites.net\/en\/wp-json\/wp\/v2\/posts\/2711\/revisions\/5140"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/multiplesclerosis-app-aca9g6eranbfeyeg.northeurope-01.azurewebsites.net\/en\/wp-json\/wp\/v2\/media\/2985"}],"wp:attachment":[{"href":"https:\/\/multiplesclerosis-app-aca9g6eranbfeyeg.northeurope-01.azurewebsites.net\/en\/wp-json\/wp\/v2\/media?parent=2711"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/multiplesclerosis-app-aca9g6eranbfeyeg.northeurope-01.azurewebsites.net\/en\/wp-json\/wp\/v2\/categories?post=2711"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/multiplesclerosis-app-aca9g6eranbfeyeg.northeurope-01.azurewebsites.net\/en\/wp-json\/wp\/v2\/tags?post=2711"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}